Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable...
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the...
Graphical abstract. Credit: Journal of Controlled Release (2024). DOI: 10.1016/j.jconrel.2023.12.043 Society learned about the value of mRNA during the COVID-19 pandemic when we saw scientists and medical professionals harness its power to deliver a vaccine for the...
Some are saying that mRNA medicines—mRNA vaccines and mRNA therapeutics alike—will open a golden era of medicine. And the enthusiasm is catching. Following the precedent set by the first mRNA-based COVID-19 vaccines, hundreds of new mRNA medicines are moving through...
ACDN-01 is the first RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024 ACDN-01 also...
